Cited by

• Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.

  Bunting PS, Goel V, Williams JI, Iscoe NA. Bunting PS, et al. CMAJ. 1999 Jan 12;160(1):70-5. CMAJ. 1999. PMID: 9934349 Free PMC article.
• Cost-effectiveness analysis of prostate cancer screening.

  Hamashima C, Yoshida K. Hamashima C, et al. Environ Health Prev Med. 2000 Oct;5(3):111-7. doi: 10.1265/ehpm.2000.111. Environ Health Prev Med. 2000. PMID: 21432194 Free PMC article.
• Prostate cancer in elderly men.

  Stangelberger A, Waldert M, Djavan B. Stangelberger A, et al. Rev Urol. 2008 Spring;10(2):111-9. Rev Urol. 2008. PMID: 18660852 Free PMC article.
• Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.

  Heijnsdijk EA, de Carvalho TM, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM, Tammela TL, Recker F, Denis L, Carlsson SV, Wever EM, Bangma CH, Schröder FH, Roobol MJ, Hugosson J, de Koning HJ. Heijnsdijk EA, et al. J Natl Cancer Inst. 2014 Dec 13;107(1):366. doi: 10.1093/jnci/dju366. Print 2015 Jan. J Natl Cancer Inst. 2014. PMID: 25505238 Free PMC article. Clinical Trial.
• Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.

  Mühlberger N, Boskovic K, Krahn MD, Bremner KE, Oberaigner W, Klocker H, Horninger W, Sroczynski G, Siebert U. Mühlberger N, et al. BMC Public Health. 2017 Jun 26;17(1):596. doi: 10.1186/s12889-017-4439-9. BMC Public Health. 2017. PMID: 28651567 Free PMC article.